NEWS DETAIL

Announcement of New Release of Synthetic Antibacterial Agent "Bactamini Combination Tablets"

Shionogi Pharma Co., Ltd. (Headquarters: Settsu City, Osaka Prefecture, President Ryuichi Kume, hereinafter "Shionogi Pharma" or "our company") is a synthetic antibacterial agent "Bacta ® Combination Tablets" (generic name: sulfamethoxazole trimethoprim). We are pleased to announce that "Bactamini ® Combination Tablets" was newly released on December 10 as an additional dosage form (formulation).

 Bacta® combination tablets are synthetic antibacterial agents for "general infectious diseases such as pneumonia and urinary tract infections" and "treatment and suppression of the onset of pneumocystis pneumonia". The diameter of the Bacta® combination tablet is 11 mm, which is large for children and the elderly to take, and because it has a unique bitterness, there is a problem that pediatric patients and elderly patients are resistant to taking the drug. In addition to the patient himself, it could be a burden to the nurses who support the medication, medical personnel such as pharmacists, and family members.

 The newly released Bactamini ® combination tablet (hereinafter referred to as "this drug") is Shionogi Pharma, National Center for Growth Medicine (Location: Setagaya-ku, Tokyo, Chairman Takashi Igarashi), Shionogi Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Osaka, President Isao Teshiroki) is a formulation that was developed by three parties and was approved for manufacturing and marketing by Shionogi Pharma on August 16, 2021 1,2 . By reducing the active ingredient content of one Bacta® combination tablet to 1/4, the diameter is reduced to 6 mm, and a sweetener is added for the purpose of reducing bitterness. By taking 4 tablets of this drug, Equivalent to one conventional tablet. Through the launch of this drug, it is expected that the resistance of pediatric patients and elderly patients to taking the drug will be reduced, and that it will further contribute to the appropriate treatment of the indicated diseases. The distribution and sales of this drug will be carried out through Shionogi Pharmaceutical Co., Ltd.

 Shionogi Pharma's mission is to become a "technology development-type manufacturing company (CDMO 3 )" that is trusted by customers, and by taking on the challenge of innovative technology development from the perspective of patients and customers, pharmaceuticals We are working to improve development efficiency and provide high value-added solution services. We will continue to contribute to the treatment of diseases through the development of new technologies, even for long-listed products that have manufacturing and marketing approval.